Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739554 · ClinicalTrials.gov registry record · Phase 1
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL
A Phase 1 study of Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by Cyclacel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
- 3
- Study locations
NCT03739554 is a Phase 1 study of Relapsed or Refractory Chronic Lymphocytic Leukemia that has completed, run by Cyclacel Pharmaceuticals. The registered enrollment target is 5 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT03739554, a Phase 1 study of Relapsed or Refractory Chronic Lymphocytic Leukemia, has completed, sponsored by Cyclacel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG CYC065
Study Locations (3)
Maryland
- Investigational Site - Baltimore
North Carolina
- Investigational Site - Charlotte
Texas
- Investigational Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2023-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739554
The ClinicalTrials.gov registry entry for NCT03739554 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT03739554 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT03739554 about?
NCT03739554 is a clinical study titled "CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL". A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
What is the current status of trial NCT03739554?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2019-01-25. Estimated completion is 2023-04-27.
What conditions does trial NCT03739554 study?
This clinical trial studies the following conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia.
What interventions are being tested in trial NCT03739554?
The interventions under investigation include: Venetoclax (DRUG), CYC065 (DRUG).
Who is sponsoring clinical trial NCT03739554?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03739554 being conducted?
This trial has 3 study locations across Maryland, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.